Schedule I and the Research Gap: How Federal Law Shapes Cannabis Science
Why the US lags behind other countries in cannabis research — and what's changing
Cannabis remains Schedule I under US federal law — the most restrictive drug classification. This creates enormous barriers to research, limiting the quality and quantity of clinical evidence. This article explains what Schedule I means in practice, how it affects research, and what the proposed rescheduling to Schedule III would change.
What Schedule I Actually Means
The Controlled Substances Act (CSA) of 1970 created five schedules for controlled substances based on medical use, abuse potential, and safety. Schedule I is the most restrictive: substances deemed to have high abuse potential, no currently accepted medical use, and lack of accepted safety under medical supervision. Cannabis (marijuana) was placed in Schedule I in 1970 — a "temporary" placement that has persisted for over 50 years.
Other Schedule I substances include heroin, LSD, and psilocybin. By contrast, cocaine is Schedule II (accepted medical use as a topical anesthetic), methamphetamine is Schedule II (approved as Desoxyn for ADHD), and fentanyl is Schedule II. The scheduling of cannabis relative to these substances has long been criticized as scientifically inconsistent.
The Practical Research Barriers
Schedule I classification creates multiple layers of research barriers: (1) DEA researcher registration — investigators must obtain a Schedule I researcher license from the DEA, a process that can take 12–18 months; (2) Institutional requirements — universities and research institutions must have DEA-registered secure storage facilities; (3) Limited supply — until 2021, all research cannabis had to come from the NIDA Drug Supply Program at the University of Mississippi, which produced cannabis that was often low-potency, poorly characterized, and unrepresentative of commercially available products; (4) Funding restrictions — federal agencies (NIH, NIDA) have historically been reluctant to fund research that might appear to support cannabis legalization; (5) Banking and financial barriers — even legal cannabis businesses struggle with banking, complicating research partnerships.
The NIDA Monopoly Problem
For decades, the University of Mississippi held the only DEA license to grow cannabis for research. The cannabis produced was often described by researchers as unlike anything available in dispensaries — lower potency, different cannabinoid profiles, and often described as resembling "lawn clippings" by some investigators. This created a fundamental validity problem: research conducted with NIDA cannabis may not reflect the effects of the high-potency, diverse products that millions of Americans actually use.
In 2021, the DEA began licensing additional cannabis cultivators for research — a significant step forward. Multiple universities and private companies have since received licenses, expanding the diversity of research-grade cannabis available. However, the licensing process remains slow and the supply chain is still developing.
How Other Countries Have Advanced
The US research gap is illustrated by comparing international progress. Canada legalized medical cannabis in 2001 and recreational cannabis in 2018, enabling naturalistic studies of real-world cannabis use at scale. The UK's GW Pharmaceuticals (now Jazz Pharmaceuticals) developed nabiximols (Sativex) and Epidiolex under a regulatory framework that allowed pharmaceutical-grade cannabis research — leading to the first FDA-approved cannabis-derived drug. Israel, where Raphael Mechoulam conducted foundational ECS research, has a robust medical cannabis research program. The Netherlands, Germany, and Australia have all developed medical cannabis frameworks that facilitate research.
The Proposed Rescheduling to Schedule III
In August 2023, the Department of Health and Human Services (HHS) recommended rescheduling cannabis from Schedule I to Schedule III. In May 2024, the DEA proposed the rescheduling — a historic step. Schedule III substances (e.g., ketamine, anabolic steroids, buprenorphine) have accepted medical uses and lower abuse potential than Schedule I or II substances.
Rescheduling to Schedule III would not legalize cannabis — it would remain a controlled substance. But it would significantly ease research barriers: investigators would no longer need Schedule I licenses; the NIDA supply monopoly would be less relevant; federal funding for cannabis research would likely increase; and the 280E tax provision (which prevents cannabis businesses from deducting business expenses) would no longer apply. The rescheduling process is ongoing as of mid-2026.
What Rescheduling Won't Fix
Even if cannabis is rescheduled to Schedule III, significant research challenges will remain. The state-federal conflict will persist — cannabis will still be federally controlled while legal in many states. The decades-long research gap cannot be quickly closed; building the evidence base for cannabis medicines requires years of well-designed clinical trials. The heterogeneity of cannabis products (hundreds of strains, multiple routes of administration, varying cannabinoid profiles) will continue to complicate research standardization. And the commercial cannabis industry's interest in marketing products ahead of the evidence will continue to outpace the science.
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making treatment decisions. See our editorial standards.